Nacer Abrouk, PhD

Clinical Trial Innovations
San Diego, California, United States

Disclosure information not submitted.

Presentation(s):

• Paper 82 - PHASE I/II STUDY OF THE TGF-BETA-TRAP ENHANCED ONCOLYTIC ADENOVIRUS, ADAPT-001, WITH AND WITHOUT AN IMMUNE CHECKPOINT INHIBITOR FOR SARCOMA PATIENTS

  Saturday, November 16, 2024
  10:30 AM – 12:00 PM PST